{
    "ticker": "VTGN",
    "name": "VistaGen Therapeutics, Inc.",
    "description": "VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with mental health disorders. Founded in 2008 and headquartered in South San Francisco, California, VistaGen focuses on addressing unmet medical needs in the treatment of depression, anxiety, and other central nervous system (CNS) disorders. The company's lead product candidate, AV-101, is an oral investigational drug designed to treat major depressive disorder (MDD) and is currently being evaluated in clinical trials. VistaGen employs a unique approach to drug development by leveraging its proprietary Human Clinical Trials in a Dish technology, which utilizes human stem cells to create a more predictive model for evaluating drug candidates. This innovative platform allows for the development of therapies that are safer and more effective than traditional treatment options. In addition to AV-101, VistaGen is advancing other product candidates aimed at addressing anxiety and the effects of chronic pain. With a dedicated team of scientists and clinicians, VistaGen is committed to transforming the treatment landscape for mental health disorders and helping patients regain control over their lives.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2008",
    "website": "https://www.vistagentherapeutics.com",
    "ceo": "Shawn Singh",
    "social_media": {
        "twitter": "https://twitter.com/VistaGen",
        "linkedin": "https://www.linkedin.com/company/vistagen-therapeutics/"
    },
    "investor_relations": "https://investors.vistagentherapeutics.com",
    "key_executives": [
        {
            "name": "Shawn Singh",
            "position": "CEO"
        },
        {
            "name": "Gary J. K. Kull",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Investigational Drugs",
            "products": [
                "AV-101",
                "PH94B"
            ]
        }
    ],
    "seo": {
        "meta_title": "VistaGen Therapeutics, Inc. | Innovating Mental Health Treatments",
        "meta_description": "Explore VistaGen Therapeutics, Inc., focused on developing innovative therapies for mental health disorders. Learn about their unique drug development approach.",
        "keywords": [
            "VistaGen",
            "Mental Health",
            "Biopharmaceuticals",
            "AV-101",
            "Anxiety Treatments",
            "Depression Treatments"
        ]
    },
    "faq": [
        {
            "question": "What is VistaGen Therapeutics known for?",
            "answer": "VistaGen Therapeutics is known for developing innovative therapies for mental health disorders, including major depressive disorder."
        },
        {
            "question": "Who is the CEO of VistaGen?",
            "answer": "Shawn Singh is the CEO of VistaGen Therapeutics, Inc."
        },
        {
            "question": "Where is VistaGen headquartered?",
            "answer": "VistaGen is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are VistaGen's main products?",
            "answer": "VistaGen's main products include AV-101 and PH94B, both investigational drugs for treating mental health conditions."
        },
        {
            "question": "When was VistaGen founded?",
            "answer": "VistaGen was founded in 2008."
        }
    ],
    "competitors": [
        "VRTX",
        "PTCT",
        "AXSM",
        "NERV"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "REGN"
    ]
}